Sakai Naomi S, Taylor Stuart A, Chouhan Manil D
1 UCL Centre for Medical Imaging, Division of Medicine, University College London , London , UK.
Br J Radiol. 2018 Sep;91(1089):20180267. doi: 10.1259/bjr.20180267. Epub 2018 Jun 14.
The association between pancreatic fat, obesity and metabolic disease is well-documented, and although a potentially exciting target for novel therapies, remains poorly understood. Non-invasive quantitative imaging-derived biomarkers can provide insights into pathophysiology and potentially provide robust trial endpoints for development of new treatments. In this review, we provide an overview of the pathophysiology of non-alcoholic fatty pancreas disease and associations with metabolic factors, obesity and diabetes. We then explore approaches to pancreatic fat quantification using ultrasound, CT and MRI, reviewing the strengths, limitations and current published evidence in the assessment of pancreatic fat. Finally, we explore the broader challenges of pancreatic fat quantification as we move toward translating these methods into the clinical setting.
胰腺脂肪、肥胖与代谢性疾病之间的关联已有充分记录,尽管它可能是新型疗法的一个令人兴奋的潜在靶点,但人们对其仍知之甚少。非侵入性定量成像衍生的生物标志物可以深入了解病理生理学,并有可能为新疗法的开发提供可靠的试验终点。在本综述中,我们概述了非酒精性脂肪性胰腺疾病的病理生理学及其与代谢因素、肥胖和糖尿病的关联。然后,我们探讨了使用超声、CT和MRI进行胰腺脂肪定量的方法,回顾了在评估胰腺脂肪方面的优势、局限性及当前已发表的证据。最后,我们探讨了在将这些方法转化为临床应用过程中,胰腺脂肪定量面临的更广泛挑战。